Methotrexate osteopathy in rheumatoid arthritis

Olga Dorota Lotkowska1, Sabine Adler2,3, Armin Zgraggen2

  • 1Clinic for Rheumatology and Immunology, Kantonsspital Aarau, Aarau, Switzerland. olga.lotkowska@gmail.com.

PubMed

Insights

Methotrexate (MTX) can cause bone problems like fractures in adults with rheumatic diseases. Discontinuing MTX led to rapid improvement in patients with MTX-associated osteopathy.

Area of Science:

  • Rheumatology
  • Bone Metabolism
  • Pharmacology

Background:

  • Methotrexate (MTX) is a common treatment for inflammatory rheumatic diseases.
  • MTX-associated osteopathy, a side effect affecting bone mineral density and fracture risk, is debated in adults on low-to-moderate doses.
  • The exact cause and clinical importance of MTX-associated osteopathy are not fully understood.

Purpose of the Study:

  • To investigate MTX-associated osteopathy in adult patients with rheumatic diseases.
  • To review clinical and radiological features of MTX-associated osteopathy.
  • To assess the impact of MTX on bone mineral density and fracture risk.

Main Methods:

  • Case series of four female patients with rheumatoid arthritis (RA) presenting with stress fractures.
  • Systematic literature review focusing on clinical and radiological characteristics of MTX-associated osteopathy.
  • Analysis of MTX effects on bone mineral density and fracture risk.

Main Results:

  • Four RA patients experienced stress fractures of the tibia and calcaneus, some with multiple fractures.
  • Patients showed rapid clinical improvement after discontinuing MTX, suggesting MTX-associated osteopathy.
  • The review highlighted common clinical and imaging findings, including band- or meander-shaped fractures.

Conclusions:

  • MTX-associated osteopathy is a potential cause of stress fractures in adults with rheumatic diseases, particularly RA.
  • Diagnosis requires careful exclusion of other fracture causes and consideration of MTX discontinuation.
  • Further research is needed to fully elucidate the pathogenesis and clinical significance of MTX-associated osteopathy.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
413
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
182
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
267
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.2K